ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price & News

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings or view top-rated stocks.

17 equities research analysts have issued twelve-month price objectives for ACADIA Pharmaceuticals' shares. Their ACAD share price forecasts range from $12.00 to $95.00. On average, they anticipate the company's share price to reach $25.43 in the next twelve months. This suggests a possible upside of 3.3% from the stock's current price.
View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts.

ACADIA Pharmaceuticals' stock was trading at $15.92 at the beginning of the year. Since then, ACAD stock has increased by 54.6% and is now trading at $24.61.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ACAD earnings forecast.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings results on Monday, May, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.06. The biopharmaceutical company earned $118.46 million during the quarter, compared to analysts' expectations of $120.29 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 35.70% and a negative net margin of 28.05%. The firm's revenue was up 2.6% on a year-over-year basis. During the same period last year, the company posted ($0.70) EPS.

ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

ACADIA Pharmaceuticals updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $520.00 million-$550.00 million, compared to the consensus revenue estimate of $556.45 million.

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

ACADIA Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (25.79%), BlackRock Inc. (6.08%), RTW Investments LP (5.07%), FMR LLC (4.84%), State Street Corp (3.44%) and Price T Rowe Associates Inc. MD (2.80%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends.

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACAD stock can currently be purchased for approximately $24.61.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $4.00 billion and generates $517.23 million in revenue each year. The biopharmaceutical company earns $-215,980,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

The company employs 514 workers across the globe.

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.